AINDEX
Markets

Aprea Therapeutics, Inc. (APRE)

APRENASDAQ-CMBiotechnology: Pharmaceutical Preparations

$0.4531

+0.0131 (+2.98%) today

At the close, Nov 17, 4:00 PM ET. Pre-market $0.4577 +1.02%

+4.07% 1D
Market cap
$6.50m
P/E
–
EPS, last 4 quarters
$-0.7000
Dividend yield
–
Day range
–
52-week range
$0.4000 to $1.49
Average volume
–
Previous close
$0.4400

Analysts

4 covering

Buy4 buy, 0 hold, 0 sell

Targets a year out average $2.73, +502.5% from here

$1.20now $0.4531$5.00

Earnings

next estimate $-0.1000

Next report

Dec 2025

+15.8%

Mar 2026

+4.3%

Jun 2026

+68.2%

Sep 2026

-12.5%

estimate reported, and the surprise

Financials

QuarterDec 2025Mar 2026Jun 2026Sep 2026
Revenue$3,000–––
Gross profit$3,000–––
Operating income-$2.64m-$3.43m-$4.03m-$5.17m
Net income-$2.46m-$3.29m-$3.59m-$4.81m

News

8 latest

The company

Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea's technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications.

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ-CM
Region
North America
Website
aprea.com

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.